News

 

 

Funding: New Awards

Richard J. Barth Jr.
Associate Professor
Immunology and Cancer Immunotherapy

  • PI/Department Funding
    A randomized Phase II Study of the effect of a low calorie diet on patients undergoing liver resection

Marc S. Ernstoff
Professor
Immunology and Cancer Immunotherapy

  • SWOG
    S0931, EVEREST: EVErolimus for renal cancer ensuing surgical therapy, a Phase III Study

Camilo E. Fadul
Professor
Immunology and Cancer Immunotherapy

  • Celldex
    An international, randomized, double-blind, controlled study of rindopepimut/GM-CSF with adjuvant temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma (The “ACT IV” Study)

Mark T. Hegel
Associate Professor
Cancer Control

  • Norris Cotton Cancer Center
    Why do men with good-risk prostate cancer choose treatment versus active surveillance? An exploratory investigation

Peter A. Kaufman
Associate Professor
Molecular Therapeutics

  • Roche Laboratories
    A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer

Kenneth Meehan
Professor
Immunology and Cancer Immunotherapy

  • PI/Department Funding
    Blood and marrow stem cell transplant outcomes database

James R. Rigas
Associate Professor
Molecular Therapeutics

  • Genentech/Roche Laboratories
    A randomized, double-blind, placebo-controlled phase III study of first-line maintenance tarceva vs tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of platinum-based chemotherapy